Usefulness of longitudinal measurements of β-amyloid1-42 in cerebrospinal fluid of patients with various cognitive and neurologic disorders [3]

Clinical Chemistry

Volumn 52, Issue 8, 2006, Pages 1604-1606

  Bouwman, Femke H ^a   Van Der Flier, Wiesje M ^a   Schoonenboom, Niki S M ^a   Van Elk, Evert J ^a   Kok, Astrid ^a   Scheltens, Philip ^a   Blankenstein, Marinus A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42];

CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; CORRELATION ANALYSIS; DEMOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; GOOD LABORATORY PRACTICE; HUMAN; LETTER; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; NEUROLOGIC DISEASE; PROTEIN CEREBROSPINAL FLUID LEVEL;

AMYLOID BETA-PROTEIN; COGNITION DISORDERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LONGITUDINAL STUDIES; NERVOUS SYSTEM DISEASES; PEPTIDE FRAGMENTS; SPECIMEN HANDLING; TIME FACTORS;

EID: 33746642088     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.070193     Document Type: Letter

References (13)

1. Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003; 2:605-13.
2. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003;352: 67-9.
3. Schoonenboom NS, Pijnenburg YA, Mulder C, Rosso SM, Van Elk EJ, Van Kamp GJ, et al. Amyloid β(1-42) and phosphorylated tau in CSF as markers for early-onset Alzheimer disease. Neurology 2004;62:1580-4.
4. Vanderstichele H, Van Kerschaver E, Hesse C, Davidsson P, Buyse MA, Andreasen N, et al. Standardization of measurement of β-amyloid(1-42) in cerebrospinal fluid and plasma. Amyloid 2000;7:245-58.
5. Pitman EJG. A note on normal correlation. Biometrika 1939;31:9-12.
6. Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, et al. Effects of processing and storage conditions on amyloid β(1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin Chem 2005;51:189-95.
7. Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, et al. Cerebrospinal fluid amyloid β peptide patterns in Alzheimer's disease patients and nondemented controls depend on sample pretreatment: Indication of carrier-mediated epitope masking of amyloid β peptides. Electrophoresis 2004;25:2912-8.
8. Tapiola T, Pirttila T, Mikkonen M, Mehta PD, Alafuzoff I, Koivisto K, et al. Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's disease. Neurosci Lett 2000;280:119-22.
9. Andreasen N, Hesse C, Davidsson P, Minthon L, Wallin A, Winblad B, et al. Cerebrospinal fluid β-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol 1999;56:673-80.
10. Kanai M, Matsubara E, Isoe K, Urakami K, Nakashima K, Arai H, et al. Longitudinal study of cerebrospinal fluid levels of tau, Aβ1-40, and Aβ1-42(43) in Alzheimer's disease: a study in Japan. Ann Neurol 1998;44:17-26.
11. Andreasen N, Minthon L, Vanmechelen E, Vanderstichele H, Davidsson P, Winblad B, et al. Cerebrospinal fluid tau and A/342 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett 1999;273:5-8.
12. de Leon MJ, Segal S, Tarshish CY, DeSanti S, Zinkowski R, Mehta PD, et al. Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment. Neurosci Lett 2002;333: 183-6.
13. Mollenhauer B, Bibl M, Trenkwalder C, Stiens G, Cepek L, Steinacker P, et al. Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer's disease. J Neural Transm 2005;112:933-48.